A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD score
Introduction: Platinum-based chemotherapy is the first-line treatment strategy for ovarian cancer patients. The dismal prognosis of ovarian cancer was shown to be stringently associated with the heterogeneity of tumor cells in response to this therapy, therefore understanding platinum sensitivity in...
Main Authors: | Fan Yang, Wei Wei, Ganghua Li, Qiongyu Lan, Xiwei Liu, Lin Gao, Chao Zhang, Jiangtao Fan, Jundong Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-09-01
|
Series: | Frontiers in Genetics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2023.1240068/full |
Similar Items
-
Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status
by: Yongmei Li, et al.
Published: (2022-03-01) -
Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
by: Andrei Havasi, et al.
Published: (2023-03-01) -
Serum lactate dehydrogenase is a possible predictor of platinum resistance in ovarian cancer
by: Asami Ikeda, et al.
Published: (2020-11-01) -
Gemcitabine–oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy
by: Mohamed Elshebeiny, et al.
Published: (2016-09-01) -
IS HIPEC BENEFICIAL IN PLATINUM RESISTANT RELAPSED OVARIAN CANCER?
by: Nicolae Bacalbasa, et al.
Published: (2019-09-01)